妓院一钑片免看黄大片,亚洲av无码成人精品国产,亚洲AV综合色区无码专区桃色,免费A级毛片在线播放不收费

Esperion Therapeutics  
生物制藥公司，專注于研究，開發和商業化的低密度脂蛋白膽固醇（LDL-C）水平升高和其他心血管代謝危險因素的患者的治療療法。

Esperion Therapeutics, Inc. is a leader in the development and commercialization of oral, small molecule therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol (LDL-C) and other cardiometabolic risk factors. ETC-1002, Esperion’s lead product candidate, is a novel, first-in-class, orally available, once-daily LDL-C lowering small molecule therapy designed to target known lipid and carbohydrate metabolic pathways to lower levels of LDL-C and to avoid many of the side effects associated with existing LDL-C lowering therapies. ETC-1002 is targeted for statin-intolerant patients with elevated levels of LDL-C.